New study on carbon nanotubes gives hope for medical applications
[PRESS RELEASE, 5 April 2010] A team of Swedish and American scientists has shown for the first time that carbon nanotubes can be broken down by an enzyme - myeloperoxidase (MPO) - found in white blood cells. Their discoveries are presented in Nature Nanotechnology and contradict what was previously believed, that carbon nanotubes are not broken down in the body or in nature. The scientists hope that this new understanding of how MPO converts carbon nanotubes into water and carbon dioxide can be of significance to medicine.
"Previous studies have shown that carbon nanotubes could be used for introducing drugs or other substances into human cells," says Bengt Fadeel, associate professor at the Swedish medical university Karolinska Institutet. "The problem has been not knowing how to control the breakdown of the nanotubes, which can caused unwanted toxicity and tissue damage. Our study now shows how they can be broken down biologically into harmless components."
Carbon nanotubes are a material consisting of a single layer of carbon atoms rolled into a tube with a diameter of only a couple of nanometres (1 nanometer = 1 billionth of a metre) and a length that can range from tens of nanometres up to several micrometers. Carbon nanotubes are lighter and stronger than steel, and have exceptional heat-conductive and electrical properties. They are manufactured on an industrial scale, mainly for engineering purposes but also for some consumer products.
Carbon nanotubes were once considered biopersistent in that they did not break down in body tissue or in nature. In recent years, research has shown that laboratory animals exposed to carbon nanotubes via inhalation or through injection into the abdominal cavity develop severe inflammation. This and the tissue changes (fibrosis) that exposure causes lead to impaired lung function and perhaps even to cancer. For example, a year or two ago, alarming reports by other scientists suggested that carbon nanotubes are very similar to asbestos fibres, which are themselves biopersistent and which can cause lung cancer (mesothelioma) in humans a considerable time after exposure.
This current study thus represents a breakthrough in nanotechnology and nanotoxicology, since it clearly shows that endogenous MPO can break down carbon nanotubes. This enzyme is expressed in certain types of white blood cell (neutrophils), which use it to neutralise harmful bacteria. Now, however, the researchers have found that the enzyme also works on carbon nanotubes, breaking them down into water and carbon dioxide. The researchers also showed that carbon nanotubes that have been broken down by MPO no longer give rise to inflammation in mice.
"This means that there might be a way to render carbon nanotubes harmless, for example in the event of an accident at a production plant," says Dr Fadeel. "But the findings are also relevant to the future use of carbon nanotubes for medical purposes."
The study was led by researchers at Karolinska Institutet, the University of Pittsburgh and the National Institute for Occupational Safety and Health (NIOSH), and was financed in part through grants from the National Institutes of Health (NIH) and the Seventh Framework Programme of the European Commission. The work was conducted as part of the NANOMMUNE project, which is coordinated by associate professor Bengt Fadeel of the Institute of Environmental Medicine, Karolinska Institutet, and which comprises a total of thirteen research groups in Europe and the USA.
Valerian E. Kagan, Nagarjun V. Konduru, Weihong Feng, Brett L. Allen, Jennifer Conroy, Yuri Volkov, Irina I. Vlasova, Natalia A. Belikova, Naveena Yanamala, Alexander Kapralov, Yulia Y. Tyurina, Jingwen Shi, Elena R. Kisin, Ashley R. Murray, Jonathan Franks, Donna Stolz, Pingping Gou, Judith Klein-Seetharaman, Bengt Fadeel, Alexander Star, Anna Shvedova
Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation
Nature Nanotechnology, in press, 4 April 2010, DOI: 10.1038/NNANO.2010.44